Product Catalog



> Antibody > Rabbit PAb Antibody > GPNMB / Osteoactivin Antibody (Antigen Affinity Purified) GPNMB / Osteoactivin Antibody (Antigen Affinity Purified)
| Catalog | Size (Price) | Quantity | In Stock | Operation | Other Information |
| 11305-RP02 |
|
YES |
|
![]() |
GPNMB / Osteoactivin Antibody ( Antigen Affinity Purified ) Datasheet
| Order or Inquire for GPNMB / Osteoactivin Antibody product | Quality antibodies | Antibody production services | ||
| Detection limit is 0.5 ng/lane in WB | ||||
| Detection limit is 0.00975 ng/well in ELISA |
GPNMB / Osteoactivin Antibody Product Information
| Immunogen : |
Recombinant Human GPNMB / Osteoactivin protein (Catalog#11305-H08H) |
| Antibody Type : | Rabbit Polyclonal Antibody ( Antibody Purification Platform ) |
| Ig Type : |
Rabbit IgG |
| Formulation : | 0.2 μm filtered solution in PBS with 5% trehalose |
| Preparation : |
Produced in rabbits immunized with purified, recombinant Human GPNMB / Osteoactivin (rh GPNMB / Osteoactivin; Catalog#11305-H08H; Q14956-2; Met 1-Pro 474). GPNMB / Osteoactivin specific IgG was purified by Human GPNMB / Osteoactivin affinity chromatography. |
GPNMB / Osteoactivin Antibody Usage Guide
|
Specificity : |
Human GPNMB / Osteoactivin |
| Western blot : | This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human GPNMB in WB. Using a DAB detection system, the detection limit for Human GPNMB is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions. |
| Direct ELISA : | This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human GPNMB. The detection limit for Human GPNMB is approximately 0.00975 ng/well. |
| Storage : | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. |
GPNMB / Osteoactivin Antibody Related Products & Topics
Related Areas:
Cancer>>Cancer Biomarkers>>GPNMB/Osteoactivin
Proteins:
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| GPNMB / Osteoactivin | Human | GPNMB/Osteoactivin Protein, Recombinant | 11305-H08H |
| GPNMB / Osteoactivin | Mouse | GPNMB / Osteoactivin Protein, Recombinant | 50475-M08H |
Antibodies:
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| Human GPNMB / Osteoactivin | WB, ELISA | GPNMB / Osteoactivin Antibody (Antigen Affinity Purified) | 11305-RP02 |
GPNMB / Osteoactivin Antibody Background
GPNMB belongs to the PMEL / NMB family, also known as Osteoactivin and Hematopoietic growth factor-inducible neurokinin 1 (HGFIN), is a transmembrane glycoprotein that is expressed in numerous cells, including osteoclasts, macrophages, dendritic cells, and tumor cells. It is suggested to influence osteoblast maturation, cell adhesion and migration. GPNMB protein acts as a downstream mediator of BMP-2 effects on osteoblast differentiation and function. GPNMB participates in bone mineralization, and functions as a negative regulator of inflammation in macrophages. Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. The early-phase upregulation of Osteoactivin expression in the tubular epithelium in response to renal injury might play a role in triggering renal interstitial fibrosis via activation of matrix metalloproteinase expression and collagen remodeling in rats. Osteoactivin as a protein that is expressed in aggressive human breast cancers and is capable of promoting breast cancer metastasis to bone.
References
- Pahl MV. et al., 2010, Clin J Am Soc Nephrol. 5 (1): 56-61.
- Abdelmagid SM. et al., 2008, Exp Cell Res. 314 (13): 2334-51.
- Haralanova-Ilieva B. et al., 2005, J Hepatol. 242 (4): 565-72.
- Abdelmagid SM. et al., 2007, J Cell Physiol. 210 (1): 26-37.
- Furochi H. et al., 2007, J Med Invest. 54 (3-4): 248-54.
GPNMB (Osteoactivin) related areas, pathways, and other information

+86-400-890-9989






